VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis

Here, Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, highlights promising treatment regimens for AL amyloidosis, including an update from the ANDROMEDA study (NCT03201965) looking at daratumumab combined with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
Dr Wechalekar also discusses ixazomib plus lenalidomide and dexamethasone (IRd).
This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc) as part of the European Hematology Association (EHA) 2020 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter